Evidence map›Paper›PMID 42348314›Full record

ArticleClinical and translational science2026

Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants.

Jingcheng Chen, Jingxuan Wu, Yuqin Song, Jiangshuo Li, Linna Li, Lijun Li, Yanhong Kong, Xiaofang Wu, Hang Yin, Mengyu Hou and 6 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jingcheng ChenResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-1199-9599
Jingxuan WuResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-3128-7601
Yuqin SongResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Jiangshuo LiResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0009-0000-0616-0281
Linna LiBeijing Pearl Biotechnology Co, Ltd, Beijing, China.
Lijun LiResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0009-0009-8079-9812
Yanhong KongResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiaofang WuResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hang YinResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Mengyu HouResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0009-0008-5893-6924
Bingyan WangResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Qiannan GaoResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ran LiResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Le WuResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Weizhe XueBeijing Pearl Biotechnology Co, Ltd, Beijing, China.
Ruihua DongResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-3463-5023

Funding

Beijing Health Science and Technology Achievements and Appropriate Technology Promotion Project BHTPP2024093the National Key Research and Development Program of China 2024YFF1207000
6 · The paper itself

Abstract

Vebreltinib is a novel, highly selective type I c-Met inhibitor developed for treating non-small cell lung cancer (NSCLC) and glioma. As in vitro studies indicate that vebreltinib is primarily metabolized via cytochrome P450 (CYP) 3A4, this study aimed to characterize the drug-drug interaction (DDI) potential of vebreltinib with strong CYP3A4 modulators. Following a preliminary single ascending dose (SAD) study to establish baseline safety and pharmacokinetics (PK) in healthy participants, a DDI study was designed to evaluate the impact of the strong CYP3A4 inducer rifampin and the strong CYP3A4 inhibitor itraconazole on vebreltinib exposure. In the CYP3A4 induction part of the DDI study, participants (n = 14) received 200 mg vebreltinib on Days 1 and 15, with rifampin (600 mg once daily) administered on Days 8-21. In the inhibition part, participants (n = 14) received 200 mg vebreltinib on Days 1 and 11. Itraconazole was administered as a loading dose (200 mg BID on Day 8) followed by maintenance dosing (200 mg QD from Days 9 to 19). PK blood samples were collected at predetermined time points. Vebreltinib plasma concentrations were assessed using a validated liquid chromatography-tandem mass spectrometry (LC-MS) method. Co-administration with rifampin reduced the AUC

Indexed as

Cytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsItraconazoleProtein Kinase InhibitorsProto-Oncogene Proteins c-metRifampinAdultArea Under CurveCytochrome P-450 CYP3ADrug InteractionsFemaleHealthy VolunteersHumansMaleMiddle AgedYoung AdultCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsItraconazoleProtein Kinase InhibitorsProto-Oncogene Proteins c-metRifampin

Identifiers

PMID42348314
PMCPMC13296813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.